secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0000950170-25-090205
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director William Meury resigns from Syndax board to become Incyte CEO
---------------------------------------------------------------------

- William Meury resigned from Syndax board effective June 24, 2025.
- Meury accepted roles of President, CEO, and board member at Incyte Corporation.
- Incyte is Syndax's collaboration partner for Niktimvo (axatilimab-csfr).
- Resignation not due to any disagreement with Syndax's operations or policies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017025090205/0000950170-25-090205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017025090205/sndx-20250624.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-090205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer